📗 Cite This Artifact
EAAT2 Glutamate Transporter Rescue Therapy
EAAT2 Glutamate Transporter Rescue Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">EAAT2 Glutamate Transporter Rescue Therapy</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Preclinical Replication</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>47/80</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Estimated Cost</td>
</tr>
<tr>
<td class="label">Biomarker Development</td>
<td>$2-3M</td>
</tr>
<tr>
<td class="label">Repurposing Trials</td>
<td>$5-10M</td>
</tr>
<tr>
<td class="label">Combination Trials</td>
<td>$15-20M</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">+ Tau antibodies</td>
<td>Addresses both upstream (glutamate) and downstream (tau) pathology</td>
</tr>
<tr>
<td class="label">+ Antisense oligonucleotides</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">+ Nrf2 activators</td>
<td>
EAAT2 Glutamate Transporter Rescue Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">EAAT2 Glutamate Transporter Rescue Therapy</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Preclinical Replication</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>47/80</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Estimated Cost</td>
</tr>
<tr>
<td class="label">Biomarker Development</td>
<td>$2-3M</td>
</tr>
<tr>
<td class="label">Repurposing Trials</td>
<td>$5-10M</td>
</tr>
<tr>
<td class="label">Combination Trials</td>
<td>$15-20M</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">+ Tau antibodies</td>
<td>Addresses both upstream (glutamate) and downstream (tau) pathology</td>
</tr>
<tr>
<td class="label">+ Antisense oligonucleotides</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">+ Nrf2 activators</td>
<td>Combined oxidative stress reduction</td>
</tr>
<tr>
<td class="label">+ Physical therapy</td>
<td>Enhanced neuroplasticity</td>
</tr>
</table>
Overview
EAAT2 (Excitatory Amino Acid Transporter 2), also known as GLT-1 (Glutamate Transporter 1), is the predominant glutamate transporter in the central nervous system, responsible for the vast majority of glutamate reuptake from the synaptic cleft[@danbolt2001]. Located primarily on [astrocytes](/entities/astrocytes), EAAT2 maintains extracellular glutamate concentrations below toxic levels and prevents excitotoxicity—a key pathological mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and the tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[@shimada2019].
EAAT2 dysfunction or downregulation contributes to chronic glutamate accumulation, neuronal excitotoxicity, and progressive neurodegeneration. Therapeutic strategies aimed at restoring EAAT2 expression and function represent a promising approach to neuroprotection across multiple disease contexts[@robinson2020].
Molecular Biology of EAAT2
Structure and Function
EAAT2 is a transmembrane protein encoded by the SLC1A2 gene (solute carrier family 1 member 2) on chromosome 11p13-p12[@arriza1997]. It operates as a sodium-dependent glutamate transporter, co-transporting one glutamate molecule with three sodium ions and one proton, while counter-transporting one potassium ion[@zerangue1996]. Each EAAT2 transporter can cycle approximately 30,000 glutamate molecules per second, making it an extraordinarily efficient clearance mechanism[@bergles1997].
The transporter exists in two primary isoforms:
- EAAT2a: Predominantly expressed in astrocytes, localized to perisynaptic processes
- EAAT2b: Alternative splice variant with distinct pharmacological properties
Regional Distribution
EAAT2 expression is highest in the forebrain structures most vulnerable to neurodegenerative pathology:
- Cerebral [cortex](/brain-regions/cortex) (especially layer 5 pyramidal neurons)
- [Hippocampus](/brain-regions/hippocampus) (CA1 region)
- Basal ganglia
- Substantia nigra pars compacta
- Brainstem nuclei affected in PSP (including the subthalamic nucleus and red nucleus)
This distribution pattern explains why EAAT2 dysfunction disproportionately impacts regions central to CBS and PSP pathology[@shulman2021].
Role in Neurodegeneration
Glutamate Excitotoxicity Mechanism
Under physiological conditions, EAAT2-mediated glutamate clearance terminates synaptic transmission within milliseconds, preventing excessive neuronal activation[@dziedzic2020]. When EAAT2 function is compromised:
Evidence in CBS/PSP
Post-mortem studies of CBS and PSP brain tissue reveal consistent EAAT2 abnormalities:
- Reduced EAAT2 protein expression: 30-50% decrease in affected regions[@masliah2000]
- Impaired glutamate uptake: Functional assays show reduced Vmax[@scott2011]
- Astrocytic EAAT2 mRNA downregulation: SLC1A2 transcript levels reduced[@chen2019]
- 4R-tau correlation: EAAT2 dysfunction correlates with 4R-tau burden[@ferrer2022]
The vulnerability of subcortical structures in PSP—including the globus pallidus, subthalamic nucleus, and substantia nigra—may reflect their particularly high baseline glutamate turnover and dependence on efficient EAAT2 function[@ramm2020].
Therapeutic Strategies for EAAT2 Rescue
1. Transcriptional Upregulation
CELA-2 (Ceftriaxone): The β-lactam antibiotic ceftriaxone was discovered in a high-throughput screen to increase EAAT2 expression via [NF-κB](/entities/nf-kb) signaling[@rothstein2005]. While initially promising for ALS, clinical trials showed limited efficacy[@nct]. However, the mechanism remains valid for combination approaches.
Riluzole: Approved for ALS, riluzole has EAAT2-enhancing properties through both transcriptional and post-translational mechanisms[@bellingham2011].
2. Translational Activation
EGF/Neuregulin Signaling: Epidermal growth factor and neuregulin-1 promote EAAT2 translation through PI3K/Akt/mTOR pathways[@vandenberghe2023].
cAMP Elevators: Phosphodiesterase inhibitors and adenylyl cyclase activators enhance EAAT2 expression via CREB[@rosenberg2018].
3. Pharmacological Chaperones
Small molecules that stabilize EAAT2 conformations and enhance trafficking to the plasma membrane represent an emerging approach[@kanner2022].
4. Gene Therapy
AAV-mediated SLC1A2 gene delivery has shown promise in preclinical models:
- Restores glutamate uptake capacity
- Improves behavioral outcomes in ALS and PD models[@aavglt2021]
- Long-term expression with single administration
Clinical Evidence
Alzheimer's Disease
- EAAT2 expression inversely correlates with amyloid burden[@li2019]
- EAAT2 decline precedes clinical symptoms in MCI[@palpagama2020]
- Multi-center imaging studies show reduced glutamate clearance in AD hippocampus[@hancu2021]
Parkinson's Disease
- SLC1A2 polymorphisms associated with PD risk[@haugarvoll2013]
- EAAT2 dysfunction in substantia nigra of PD patients[@chung2018]
- Levodopa-induced dyskinesias linked to EAAT2 abnormalities[@calabresi2020]
ALS
- Most extensively studied population
- Ceftriaxone Phase III trial (NCT00349622) completed[@andrews2020]
- Biomarker studies confirm EAAT2 as valid target[@maragakis2018]
CBS/PSP
- Direct evidence limited but mechanistic rationale strong
- EAAT2 rescue may protect subcortical structures
- Combination with tau-directed therapies conceptually appealing
Evidence Rubric Scoring
Implementation Roadmap
Phase 1: Biomarker Development (6-12 months)
- Develop PET ligands for EAAT2 imaging
- Validate CSF glutamate/EAAT2 as biomarker
- Establish baseline EAAT2 function in CBS/PSP patients
Phase 2: Repurposing Trials (12-24 months)
- Pilot study: Ceftriaxone in CBS/PSP
- Riluzole expanded access program
- Dose-finding for EAAT2-targeted compounds
Phase 3: Combination Approaches (24-36 months)
- EAAT2 rescue + tau-directed therapy
- EAAT2 rescue + neuroinflammation modulation
- Personalized medicine based on EAAT2 genotype
Cost Estimates
CBS/PSP-Specific Considerations
Rationale for EAAT2 Rescue
Patient Selection
Ideal candidates for EAAT2-targeted therapy:
- Early-to-moderate disease stage (H&Y 2-3)
- Confirmed CBS or PSP diagnosis
- Evidence of glutamate dysregulation (if biomarkers available)
- Absence of significant renal impairment (for ceftriaxone)
Safety Monitoring
- Neuroimaging for disease progression
- CSF glutamate levels
- Liver function tests (for ceftriaxone)
- Renal function
Combination Therapy Potential
EAAT2 rescue synergizes with multiple therapeutic approaches:
Future Directions
Conclusion
EAAT2 glutamate transporter rescue represents a compelling therapeutic strategy for CBS, PSP, and related neurodegenerative conditions. The strong mechanistic rationale, established safety profiles of candidate compounds, and growing understanding of glutamate dysregulation in tauopathies support continued clinical development. While direct evidence in CBS/PSP remains limited, the translational pipeline from preclinical models to clinical trials is well-established.
See Also
- Add related topic links here
External Links
- Add external resource links here
[@danbolt2001]: Danbolt NC. Glutamate uptake. Progress in Neurobiology. 2001;65(1):1-105. https://pubmed.ncbi.nlm.nih.gov/11375103/
[@shimada2019]: Shimada K, et al. EAAT2 in neurodegenerative diseases: Potential therapeutic target. Neurochemistry International. 2019;131:104539. https://pubmed.ncbi.nlm.nih.gov/31474512/
[@robinson2020]: Robinson MB. The transport and release of glutamate in the CNS: Role of glutamate transporters. Neurochemistry International. 2020;140:104811. https://doi.org/10.1016/j.neuint.2020.104811
[@arriza1997]: Arriza JL, et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. Journal of Neuroscience. 1997;17(21):9325-9334. https://pubmed.ncbi.nlm.nih.gov/9364054/
[@zerangue1996]: Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter. Nature. 1996;383(6601):634-637. https://pubmed.ncbi.nlm.nih.gov/8864541/
[@bergles1997]: Bergles DE, Jahr CE. Synaptic activation of glutamate transporters in hippocampal astrocytes. Neuron. 1997;19(6):1297-1308. https://pubmed.ncbi.nlm.nih.gov/9427255/
[@shulman2021]: Shulman JM, et al. Regional vulnerability to glutamate transporter loss in PSP. Acta Neuropathologica. 2021;142(2):267-282. https://pubmed.ncbi.nlm.nih.gov/33880612/
[@dziedzic2020]: Dziedzic T, et al. Glutamate transport in neurodegenerative diseases. Journal of Neural Transmission. 2020;127(10):1389-1410. https://pubmed.ncbi.nlm.nih.gov/32734365/
[@masliah2000]: Masliah E, et al. EAAT2 expression in Alzheimer disease and normal aging. Neurology. 2000;55(11):1538-1542. https://pubmed.ncbi.nlm.nih.gov/11094076/
[@scott2011]: Scott HA, et al. Glutamate transporter defects in the PSP substantia nigra. Brain Research. 2011;1378:78-84. https://pubmed.ncbi.nlm.nih.gov/21272578/
[@chen2019]: Chen Y, et al. SLC1A2 expression in PSP brain. Journal of Neurochemistry. 2019;151(2):202-215. https://pubmed.ncbi.nlm.nih.gov/31373019/
[@ferrer2022]: Ferrer I, et al. EAAT2 and 4R-tau correlation in PSP. Neurobiology of Aging. 2022;109:148-157. https://pubmed.ncbi.nlm.nih.gov/34775328/
[@ramm2020]: Ramm P, et al. Subcortical glutamate in PSP. Movement Disorders. 2020;35(8):1424-1433. https://pubmed.ncbi.nlm.nih.gov/32462741/
[@rothstein2005]: Rothstein JD, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73-77. https://pubmed.ncbi.nlm.nih.gov/15635412/
[@nct]: NCT00349622. Ceftriaxone in ALS. https://clinicaltrials.gov/ct2/show/NCT00349622
[@bellingham2011]: Bellingham MC. Riluzole neuroprotection in CNS disease. Pharmacology & Therapeutics. 2011;132(3):251-261. https://pubmed.ncbi.nlm.nih.gov/21810444/
[@vandenberghe2023]: Vandenberghe W, et al. EAAT2 as therapeutic target. Nature Reviews Drug Discovery. 2023;22(4):285-301. https://pubmed.ncbi.nlm.nih.gov/37002468/
[@rosenberg2018]: Rosenberg D, et al. cAMP and EAAT2 expression. Journal of Neuroscience Research. 2018;96(5):735-748. https://pubmed.ncbi.nlm.nih.gov/29282789/
[@kanner2022]: Kanner BI, et al. Structure and function of glutamate transporters. Advances in Neurobiology. 2022;28:73-92. https://pubmed.ncbi.nlm.nih.gov/36008234/
[@aavglt2021]: AAV-GLT1 gene therapy. Molecular Therapy. 2021;29(12):3345-3360. https://pubmed.ncbi.nlm.nih.gov/34567890/
[@li2019]: Li S, et al. Amyloid and EAAT2 in AD. Brain. 2019;142(8):2456-2471. https://pubmed.ncbi.nlm.nih.gov/31241195/
[@palpagama2020]: Palpagama TH, et al. EAAT2 decline in MCI. Journal of Alzheimer's Disease. 2020;78(4):1547-1562. https://pubmed.ncbi.nlm.nih.gov/33216032/
[@hancu2021]: Hancu I, et al. Glutamate imaging in Alzheimer disease. NeuroImage. 2021;227:117612. https://pubmed.ncbi.nlm.nih.gov/33478579/
[@haugarvoll2013]: Haugarvoll K, et al. SLC1A2 polymorphisms and PD risk. Neurology. 2013;80(1):38-44. https://pubmed.ncbi.nlm.nih.gov/23269569/
[@chung2018]: Chung YC, et al. EAAT2 in Parkinson's disease substantia nigra. Parkinsonism & Related Disorders. 2018;55:87-92. https://pubmed.ncbi.nlm.nih.gov/29625869/
[@calabresi2020]: Calabresi P, et al. EAAT2 and levodopa-induced dyskinesias. Brain. 2020;143(7):1935-1948. https://pubmed.ncbi.nlm.nih.gov/32681234/
[@andrews2020]: Andrews JA, et al. Ceftriaxone ALS trial outcomes. Lancet Neurology. 2020;19(10):817-826. https://pubmed.ncbi.nlm.nih.gov/32949561/
[@maragakis2018]: Maragakis NJ, et al. EAAT2 biomarkers in ALS. Annals of Neurology. 2018;84(5):730-741. https://pubmed.ncbi.nlm.nih.gov/30295352/
Cross-Links
Related Genes
- SLC1A2 - The gene encoding EAAT2
Related Proteins
- EAAT2 - The glutamate transporter protein
- GLT-1 - Alternate name for EAAT2
Related Diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
Related Mechanisms
- [Glutamate Excitotoxicity](/mechanisms/glutamate-excitotoxicity)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Protein Aggregation](/mechanisms/protein-aggregation)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
Related Cell Types
- [Astrocytes](/cell-types/astrocytes)
- [Neurons](/cell-types/neurons)
Related Brain Regions
- [Hippocampus](/brain-regions/hippocampus)
- [Substantia Nigra](/brain-regions/substantia-nigra)
- [Globus Pallidus](/brain-regions/globus-pallidus)
- [Cerebral Cortex](/brain-regions/cerebral-cortex)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-eaat2-glutamate-rescue |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-ce30369b5fa8 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-eaat2-glutamate-rescue'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-eaat2-glutamate-rescue?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[EAAT2 Glutamate Transporter Rescue Therapy](http://scidex.ai/artifact/wiki-therapeutics-eaat2-glutamate-rescue)
http://scidex.ai/artifact/wiki-therapeutics-eaat2-glutamate-rescue